Depression Mental and Behavioural Disorders Depressive episode
Conditions
Interventions
Two groups randomly allocated to:
1. Placebo
2. 1 g/day ethyl EPA
on a double-blind basis.
Patients who completed the 12-week randomisation phase of the trial were invited to take part in a further
Sponsors
Laxdale Ltd (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Written informed consent 2. Score of greater than or equal to 16 on the Hamilton Depression Rating Scale (HDRS) 3.Treatment for greater than or equal to 8 weeks with one or more standard antidepressant, at stable dose for greater than or equal to 3 weeks 4. Currently receiving at least the minimum therapeutic dose of one or more standard antidepressant, as defined in the British National Formulary (BNF) 5. Diagnosis of major depressive disorder (Diagnostic and Statistical Manual of Mental Disorders, Fourth edition [DSM-IV]) 6. Male or female of any race aged 18-75
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed